FBInvestor
Stocks / Lineage Cell Therapeutics In
Institutional Ownership

Lineage Cell Therapeutics In

CUSIP 53566P109COMLCTXQ1 2026

Institutional Holders
127
13F filers
Shares Held
101.94M
Aggregate institutional
Institutional Value
$160.26M
Q1 2026
Net New Holders
+10
22 new · 12 closed

Institutional Ownership Trend

Aggregate 13F value by quarter

Multi-quarter trend — upgrade to see history

Upgrade

Position Activity

Q1 2026

New positions22
Increased37
Decreased25
Sold out12

Institutional Holders

127 funds hold this security · Q1 2026

#FundSharesValueΔ SharesActivity
1Broadwood Capital Inc49.56M$78.31M0Held
2Defender Capital, LLC.6.73M$10.63M99.5KReduced
3Millennium Management LLC5.56M$8.79M+3.45MAdded
4Raffles Associates LP5.36M$8.47M0Held
5Fifth Third Bancorp4.60M$7.27M+4.60MNew
6Blackrock, Inc.3.86M$6.11M+30.6KAdded
7Armistice Capital, LLC3.18M$5.03M+3.18MNew
8Marshall Wace, LLP3.07M$4.84M+1.70MAdded
9Geode Capital Management, LLC2.52M$3.99M+61.9KAdded
10Renaissance Technologies LLC2.13M$3.36M279.7KReduced

117 more institutional holders on Premium

See every fund holding Lineage Cell Therapeutics In, with full quarter-over-quarter share changes.

Unlock all holders